Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>HCA Healthcare shared its quarterly financial performance for the second quarter of 2024, emphasizing positive growth across many key areas, amid some challenges inherent in the healthcare industry.</li><li>The company's earnings per share adjusted saw a significant increase by 28%, rising to $5.50, driven by robust volume growth across its markets and service lines.</li><li>This growth reflects a concerted effort from HCA Healthcare to optimize operations and improve patient outcomes.</li></ul>

HCA Healthcare shared its quarterly financial performance for the second quarter of 2024, emphasizing positive growth across many key areas, amid some challenges inherent in the healthcare industry.The company's earnings per share adjusted saw a significant increase by 28%, rising to $5.50, driven by robust volume growth across its markets and service lines.This growth reflects a concerted effort from HCA Healthcare to optimize operations and improve patient outcomes.

HCA Healthcare Inc.: How Is Its Organic Growth Strategy Shaping Up? - Major Drivers

<ul><li>HCA Healthcare, one of the largest U.S. health systems, has shown robust quarterly results backed by sustained fundamentals in their business.</li><li>The momentum primarily results from broad-based volume growth, improved payer mix, and healthy operating margins.</li><li>While HCA Healthcare generally presents a promising outlook for the rest of the year, the management underscores uncertainties that diverse risks may pose.</li></ul>

HCA Healthcare, one of the largest U.S. health systems, has shown robust quarterly results backed by sustained fundamentals in their business.The momentum primarily results from broad-based volume growth, improved payer mix, and healthy operating margins.While HCA Healthcare generally presents a promising outlook for the rest of the year, the management underscores uncertainties that diverse risks may pose.

HCA Healthcare: How Long Is The Continued Strength In Demand for Healthcare Services Expected To Last? - Major Drivers

<ul><li>HCA Healthcare Inc.</li><li>had a robust fourth quarter in 2023, which exceeded expectations across most business dimensions.</li><li>Demand for services remained high across the company's diverse portfolio.</li></ul>

HCA Healthcare Inc.had a robust fourth quarter in 2023, which exceeded expectations across most business dimensions.Demand for services remained high across the company's diverse portfolio.

HCA Healthcare: Strong Demand Indicators Could Be A Major Driving Force! - Key Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asahi-intecc-co-ltd" target="_blank" data-smartkarma-citation="entities:15915:1" rel="noopener">Asahi Intecc (7747 JP)</a> is poised for multi-year growth through strong market demand for its technically superior guidewires, market leadership positioning, new product launches, and direct marketing initiatives.</li>
<li>In FY24, Asahi Intecc aims to achieve revenue of ¥100B (+11% YoY), a significant milestone. The company targets revenue of ¥110B and an operating profit margin of 23–25% in FY26.</li>
<li>Asahi Intecc is expected to be a continued beneficiary of global procedure volume recovery. The company is likely to achieve its medium-term business plan ahead of schedule.</li>
</ul>



Asahi Intecc (7747 JP) is poised for multi-year growth through strong market demand for its technically superior guidewires, market leadership positioning, new product launches, and direct marketing initiatives.
In FY24, Asahi Intecc aims to achieve revenue of ¥100B (+11% YoY), a significant milestone. The company targets revenue of ¥110B and an operating profit margin of 23–25% in FY26.
Asahi Intecc is expected to be a continued beneficiary of global procedure volume recovery. The company is likely to achieve its medium-term business plan ahead of schedule.


2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>The S&amp;P 500 (SPX) is back to test YTD highs and important resistance in the 5670-5783 range. This is an important target/resistance area we have discussed for weeks.</li>
<li>Using the 2007 SPX topping analog suggests a 2% or less move above the prior all-time high set in July at 5670 before topping, which gives the 5783 number.</li>
<li>As long as SPX does not have a weekly close above 5783 we continue to recommend reducing risk and shifting to defensives,and this is the ideal time to do so.</li>
</ul>


The S&amp;P 500 (SPX) is back to test YTD highs and important resistance in the 5670-5783 range. This is an important target/resistance area we have discussed for weeks.
Using the 2007 SPX topping analog suggests a 2% or less move above the prior all-time high set in July at 5670 before topping, which gives the 5783 number.
As long as SPX does not have a weekly close above 5783 we continue to recommend reducing risk and shifting to defensives,and this is the ideal time to do so.


SPX Testing Resistance as Rate Cut Cycle Begins; SPX 5670-5783 Is Resistance, 2007 Analog on Track

United States

HCA Healthcare, Inc.  operates hospitals.  The Company operates acute care hospitals, outpatient facilities, clinics and other patient care delivery settings.  HCA operates hospitals in the United States and the United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

HCA Healthcare, Inc. (HCA US)

HCA Healthcare Inc.: How Is Its Organic Growth Strategy Shaping Up? - Major Drivers

HCA Healthcare shared its quarterly financial performance for the second quarter of 2024, emphasizing positive growth across many key areas, amid...

Baptista Research

HCA Healthcare: How Long Is The Continued Strength In Demand for Healthcare Services Expected To Last? - Major Drivers

HCA Healthcare, one of the largest U.S. health systems, has shown robust quarterly results backed by sustained fundamentals in their business. The...

Baptista Research

HCA Healthcare: Strong Demand Indicators Could Be A Major Driving Force! - Key Drivers

HCA Healthcare Inc. had a robust fourth quarter in 2023, which exceeded expectations across most business dimensions. Demand for services remained...

Baptista Research

2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

Asahi Intecc is poised for double-digit sales growth through FY26, driven by strong market demand for guidewires, market leadership positioning,...

Tina Banerjee

SPX Testing Resistance as Rate Cut Cycle Begins; SPX 5670-5783 Is Resistance, 2007 Analog on Track

$SPX Testing Resistance as Rate Cut Cycle Begins; SPX 5670-5783 is Resistance, 2007 Analog on Track if Below 5783. Still Neutral, prefer to sell...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)